Phio制药在其临床试验最终队列研究中取得突破性进展——当使用最高剂量浓度时，病理缓解率高达85%。该数据来源于7例参与试验的患者群体，其中6例表现出显著治疗效果。这一结果不仅验证了剂量递增策略的有效性，更为后续临床开发路径提供了关键依据。
Phio制药在其临床试验最终队列研究中取得突破性进展——当使用最高剂量浓度时，病理缓解率高达85%。该数据来源于7例参与试验的患者群体，其中6例表现出显著治疗效果。这一结果不仅验证了剂量递增策略的有效性，更为后续临床开发路径提供了关键依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.